Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation
When the liver converts TMA to a neutral compound called TMAO via the enzyme FMO3 the smell disappears
Setting Realistic Weight Loss Expectations The Phase 3 ATTAIN-1 trial showed mean weight loss of approximately 11% at 72 weeks for the orforglipron 36 mg group
Wu KP, Chen JS, Lin JW, Zhu EY, Xu XC, Yan XH, et al
Transduced cells were selected with 2 g/ml puromycin (Sigma-Aldrich, TR-1003-G).The DNA sequences of these shRNA genes were as follows: sh-NRF2-a forward: 5- CCG GCT TGC ATT AAT TCG GGA TAT ACT CGA GTA TAT CCC GAA TTA ATG CAA GTT TTT G-3 and reverse, 5- AAT TCA AAA ACT TGC ATT AAT TCG GGA TAT ACT CGA GTA TAT CCC GAA TTA ATG CAA G-3, sh-NRF2-b forward: 5-CCG GAG AGC AAG ATT TAG ATC ATT TCT CGA GAA ATG ATC TAA ATC TTG CTC TTT TTT G-3 and reverse, 5- AAT TCA AAA AAG AGC AAG ATT TAG ATC ATT TCT CGA GAA ATG ATC TAA ATC TTG CTC T-3, sh-C forward: 5- CCG GGC AAG CTG ACC CTG AAG TTC ACT CGA GTG AAC TTC AGG GTC AGC TTG CTT TTT G-3 and reverse, 5- AAT TCA AAA AGC AAG CTG ACC CTG AAG TTC ACT CGA GTG AAC TTC AGG GTC AGC TTG C-3
The analysis found that: At 12 months, Omada members largely maintained their weight at GLP-1 discontinuation, with an average 0.8% weight change At 12 months, 63.2% of members maintained or continued to lose weight At 6 and 9 months, Omada members demonstrated 0.03% and 0.6% average weight change, respectively These findings suggest that Omada can play an integral role in supporting members during important transitions in their GLP-1 journey, including helping members maintain their weight well after GLP-1 discontinuation.
